The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have a KRAS pG12C mutation in lung or colorectal cancer. The purpose of this study to evaluate an investigational drug, sotorasib in combination with chemotherapies or another investigational drug. The safety and effects of the investigational treatment will be assessed for this study.
Participation includes a screening period, treatment cycles of 3-4 weeks with sotorasib (taken by mouth daily) plus chemotherapy and/or additional investigational drugs, and a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. You may remain on the study as long as the treatment is still helping your disease. Study specific test will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03600883
You may receive compensation and possibly reimbursement to help with travel costs if you participate on this study.